Propanc Biopharma (PPCB) Net Cash Flow (2011 - 2025)
Propanc Biopharma (PPCB) posted quarterly Net Cash Flow of -$36308.0 for Q4 2025, down 149.37% year-over-year from $73545.0 in Q4 2024, and down 106.2% quarter-over-quarter from $585214.0 in Q3 2025.
Propanc Biopharma (PPCB) Net Cash Flow (2011 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Net Cash Flow for 15 consecutive years, with -$36308.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Cash Flow fell 149.37% year-over-year to -$36308.0; the TTM figure through Dec 2025 stood at $580765.0 (up 6675.93% YoY), while the FY2025 annual figure was $85588.0, up 1163.11% from the prior year.
- Net Cash Flow eased to -$36308.0 in Q4 2025 per PPCB's latest filing, from $585214.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $585214.0 in Q3 2025 and bottomed at -$77973.0 in Q2 2023.
- Historically, Net Cash Flow has averaged $34996.6 across 5 years, with a median of $1897.5 in 2022.
- Annual changes were most pronounced in 2022 — Net Cash Flow slumped 367.72% — and 2025, when it surged 3053.24%.
- Propanc Biopharma's Net Cash Flow stood at $130165.0 in 2021, then slumped by 80.97% to $24773.0 in 2022, then jumped by 41.46% to $35044.0 in 2023, then surged by 109.86% to $73545.0 in 2024, then sank by 149.37% to -$36308.0 in 2025.
- Business Quant data shows PPCB's Net Cash Flow at -$36308.0 in Q4 2025, $585214.0 in Q3 2025, and -$19430.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | -36,308.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -36,308.00 |
| Dec 31, 2025 | -36,308.00 |
| Sep 30, 2025 | 585,214.00 |
| Sep 30, 2025 | 585,214.00 |
| Jun 30, 2025 | -19,430.00 |
| Jun 30, 2025 | -19,430.00 |
| Mar 31, 2025 | 51,289.00 |
| Mar 31, 2025 | 51,289.00 |
| Dec 31, 2024 | 73,545.00 |
| Dec 31, 2024 | 73,545.00 |
| Sep 30, 2024 | -19,816.00 |
| Sep 30, 2024 | -19,816.00 |
| Jun 30, 2024 | -8,992.00 |
| Jun 30, 2024 | -8,992.00 |
| Mar 31, 2024 | -36,166.00 |
| Mar 31, 2024 | -36,166.00 |
| Dec 31, 2023 | 35,044.00 |
| Dec 31, 2023 | 35,044.00 |
| Sep 30, 2023 | 16,890.00 |
| Sep 30, 2023 | 16,890.00 |